Why the study?
Targeted CHD screening effectiveness is reduced by low severe CHD prevalence, improved second-trimester ultrasound detection, and high severe CHD rates in low-risk pregnancies. The authors aimed to determine when additional fetal echocardiography significantly increases sensitivity and decreases false negatives.
Does the addition of fetal echocardiography to second-trimester ultrasound improve the detection of severe congenital heart disease in high-risk pregnancies?
Does the addition of fetal echocardiography to second-trimester ultrasound improve the detection of severe congenital heart disease in high-risk pregnancies?
Adding fetal echocardiography to a normal second-trimester ultrasound in high-risk pregnancies provides only marginal benefits in detecting severe congenital heart disease, requiring significant resource utilization.
Marginal gains from adding FE after normal ultrasound in high-risk pregnancies; leaves open optimal referral thresholds for prospective study.
BACKGROUND: The effectiveness of screening strategies targeting pregnancies at higher risk of congenital heart disease (CHD) is reduced by the low prevalence of severe CHD, the increase in CHD detection rates by second-trimester ultrasound (U/S), and the high proportion of severe CHD in low-risk pregnancies. We aimed to determine situations in which additional screening by fetal echocardiography (FE) would result in a significant increase in sensitivity and a sizable decrease in the false-negative rate of detection of severe CHD. METHODS: We simulated the change in the numbers of detected severe CHD cases when FE is offered to women with a normal second-trimester U/S who have a higher risk of bearing a child with CHD, compared to U/S alone. The primary outcome was the increase in sensitivity. Secondary outcomes were the number needed to screen and the reduction in the rate of missed cases. RESULTS: For an U/S sensitivity of 60%, the addition of FE in pregnancies at high risk of CHD (risk ratio 3.5; range: 2 to 5) increased sensitivity by 2.4 percentage points (1.1 to 7.9). The number needed to screen to detect one additional case of severe CHD was 436 (156 to 952). The rate of additional severe CHD cases detected by FE was 4 per 100,000 pregnancies (2 to 32). CONCLUSIONS: The addition of FE to U/S for severe CHD prenatal screening in pregnancies at high risk of CHD yielded marginal benefits in terms of increased sensitivity and decreased rates of false negatives, at the expense of significant resource utilization.
No takes yet. Share an insight, caveat, or question.
Bellavance et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: